> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Re-org Outlines Oncology Center of Excellence Role
- URL: https://www.fdaweb.com/fda-re-org-outlines-oncology-center-of-excellence-role/
- Published: 2017-07-27T12:00:00.000Z
- Updated: 2026-09-14T22:36:40.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139235

*Federal Register* notice: FDA has announced a new organizational structure for the Office of the Medical Products and Tobacco to establish the Oncology Center of Excellence (OCE) that is intended to optimize an integrated cross-Center regulatory approach and enhance the coordination of medical product development in oncology. The OCE will be responsible, in accordance with an Inter-Center Agreement between OCE, CBER, CDER, and CDRH, for the clinical portion of medical oncology and malignant hematology applications involving drugs, biologics, and devices. Other functions of the OCE include: Harmonization of cancer-specific regulatory approaches; coordination of oncology-specific regulatory science initiatives and outreach; implementation of cross-center oncology-focused meetings; stakeholder engagement to the external community of other government agencies, industry, academia, professional societies, and patient advocacy groups; and communication with international regulatory agencies. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-07-27/pdf/2017-15443.pdf?ref=fdaweb.com).